Literature DB >> 12489075

Upregulation of fatty acid synthase gene expression in experimental chronic renal failure.

Marek Szolkiewicz1, Tomasz Nieweglowski, Justyna Korczynska, Elzbieta Sucajtys, Ewa Stelmanska, Elzbieta Goyke, Julian Swierczynski, Boleslaw Rutkowski.   

Abstract

Hypertriglyceridemia associated with chronic renal failure (CRF) and elevated plasma concentration of very-low-density lipoprotein (VLDL) are thought to be a consequence of the depressed lipoprotein lipase and hepatic lipase activities and impaired clearance of lipoproteins. However, there is some evidence that the lipoproteins overproduction might also contribute to hypertriglyceridemia in CRF. This study was performed to test the hypothesis that the increased rate of lipogenesis consequent to upregulation of fatty acid synthase (FAS), a key lipogenic enzyme, gene expression could contribute to overproduction of triacylglycerols and to hypertriglyceridemia in CRF. FAS activity, FAS protein mass (Western blot analysis), and FAS mRNA level (Northern blot analysis) in liver and epididymal white adipose tissue (WAT) were measured in male Wistar rats 6 weeks after subtotal (5 of 6) nephrectomy or sham operation. Moreover, the rate of lipogenesis in WAT was determined. The CRF group showed significant increase in FAS gene expression (measured as activity, mRNA, and protein abundance) in both liver and WAT. This was associated with the increase in the lipogenesis rate and with the increase in plasma triacylglycerol and VLDL concentrations. Our results suggest that not only decreased removal, but also an increase of triacylglycerol production could contribute, in part, to the CRF-associated hyperlipidemia. Upregulation of FAS gene expression, shown in this report for the first time, reveals another factor involved in disturbed lipid metabolism in CRF. It seems that elevated plasma insulin and cytokine concentration could play an important role in the mechanism responsible for the increased FAS gene expression in CRF. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12489075     DOI: 10.1053/meta.2002.36302

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes.

Authors:  J Berndt; P Kovacs; K Ruschke; N Klöting; M Fasshauer; M R Schön; A Körner; M Stumvoll; M Blüher
Journal:  Diabetologia       Date:  2007-05-11       Impact factor: 10.122

2.  Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models.

Authors:  Santosh L Saraf; Justin R Sysol; Alexandru Susma; Suman Setty; Xu Zhang; Krishnamurthy P Gudehithlu; Jose A L Arruda; Ashok K Singh; Roberto F Machado; Victor R Gordeuk
Journal:  Transl Res       Date:  2018-02-02       Impact factor: 7.012

3.  Serum fatty acid synthase as a marker of pancreatic neoplasia.

Authors:  Kim Walter; Seung-Mo Hong; Sinead Nyhan; Marcia Canto; Neal Fedarko; Alison Klein; Margaret Griffith; Noriyuki Omura; Susan Medghalchi; Frank Kuhajda; Michael Goggins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

4.  Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease.

Authors:  Jin Hui Tang; Yu Wen; Fei Wu; Xiao Y Zhao; Mei X Zhang; Jie Mi; Katherine Cianflone
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

5.  Ozone therapy on rats submitted to subtotal nephrectomy: role of antioxidant system.

Authors:  José Luis Calunga; Zullyt B Zamora; Aluet Borrego; Sarahí del Río; Ernesto Barber; Silvia Menéndez; Frank Hernández; Teresita Montero; Dunia Taboada
Journal:  Mediators Inflamm       Date:  2005-08-31       Impact factor: 4.711

6.  Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor.

Authors:  Xiaoqing Wang; Guoqiang Du; Yidi Wu; Yongfei Zhang; Feng Guo; Wei Liu; Rongde Wu
Journal:  Int J Oncol       Date:  2019-12-20       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.